A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer

Bolla, 2010, External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study, Lancet Oncol, 11, 1066, 10.1016/S1470-2045(10)70223-0

Roach, 2008, Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610, J Clin Oncol, 26, 585, 10.1200/JCO.2007.13.9881

Widmark, 2009, Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial, Lancet, 373, 301, 10.1016/S0140-6736(08)61815-2

Mason, 2015, Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer, J Clin Oncol, 33, 2143, 10.1200/JCO.2014.57.7510

Klotz, 2003, Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy, J Urol, 170, 791, 10.1097/01.ju.0000081404.98273.fd

Schulman, 2000, 4-year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer, Eur Urol, 38, 706, 10.1159/000020366

AstraZeneca

Rathkopf, 2008, Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer, J Clin Oncol, 26, 2959, 10.1200/JCO.2007.15.1928

U.S. Department of Health and Human Services, Food and Drug Administration

James, 2015, Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019), Eur Urol, 67, 1028, 10.1016/j.eururo.2014.09.032

Scher, 2008, Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group, J Clin Oncol, 26, 1148, 10.1200/JCO.2007.12.4487

Tzelepi, 2011, Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment, J Clin Oncol, 29, 2574, 10.1200/JCO.2010.33.2999

Gleave, 2001, Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects, J Urol, 166, 500, 10.1016/S0022-5347(05)65971-X

Taplin, 2014, Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study, J Clin Oncol, 32, 3705, 10.1200/JCO.2013.53.4578

Hussain, 2006, Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162), J Clin Oncol, 24, 3984, 10.1200/JCO.2006.06.4246

Muacevic, 2013, Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer, Urol Oncol, 31, 455, 10.1016/j.urolonc.2011.02.023

Ost, 2015, Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis, Eur Urol, 69, 9, 10.1016/j.eururo.2015.07.004

Ristau, 2016, The role of radical prostatectomy in high-risk localized, node-positive and metastatic prostate cancer, Future Oncol, 12, 687, 10.2217/fon.15.355

Logothetis, 2016, Is it time to re-examine the prostate cancer treatment paradigm by targeting the interaction between the prostate and metastases?, J Clin Oncol, 34, 2810, 10.1200/JCO.2016.68.4738

Grossman, 2003, Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer, N Engl J Med, 349, 859, 10.1056/NEJMoa022148

Donohue, 1982, Cytoreductive surgery for metastatic testis cancer: tissue analysis of retroperitoneal masses after chemotherapy, J Urol, 127, 1111, 10.1016/S0022-5347(17)54256-1

Flanigan, 2001, Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer, N Engl J Med, 345, 1655, 10.1056/NEJMoa003013

Bartlett, 2015, The rise in metastasectomy across cancer types over the past decade, Cancer, 121, 747, 10.1002/cncr.29134

Engel, 2010, Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer, Eur Urol, 57, 754, 10.1016/j.eururo.2009.12.034

Steuber, 2011, Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study, BJU Int, 107, 1755, 10.1111/j.1464-410X.2010.09730.x

Culp, 2014, Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study, Eur Urol, 65, 1058, 10.1016/j.eururo.2013.11.012

Satkunasivam, 2015, Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-Medicare analysis, J Urol, 194, 378, 10.1016/j.juro.2015.02.084

Rusthoven, 2016, Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer, J Clin Oncol, 34, 2835, 10.1200/JCO.2016.67.4788

Heidenreich, 2015, Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study, J Urol, 193, 832, 10.1016/j.juro.2014.09.089

Sooriakumaran, 2016, A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation, Eur Urol, 69, 788, 10.1016/j.eururo.2015.05.023

Sweeney, 2015, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer, N Engl J Med, 373, 737, 10.1056/NEJMoa1503747

James, 2015, Docetaxel and/or zoledronic acid for hormone-naive prostate cancer: first overall survival results from STAMPEDE (NCT00268476), J Clin Oncol, 33

Fizazi, 2015, Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial, Lancet Oncol, 16, 787, 10.1016/S1470-2045(15)00011-X

James, 2016, Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial, Lancet, 387, 1163, 10.1016/S0140-6736(15)01037-5